Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 42

1.

Features of Human Decidual NK Cells in Healthy Pregnancy and During Viral Infection.

Jabrane-Ferrat N.

Front Immunol. 2019 Jun 28;10:1397. doi: 10.3389/fimmu.2019.01397. eCollection 2019. Review.

2.

A CRISPR Activation Screen Identifies Genes That Protect against Zika Virus Infection.

Dukhovny A, Lamkiewicz K, Chen Q, Fricke M, Jabrane-Ferrat N, Marz M, Jung JU, Sklan EH.

J Virol. 2019 Jul 30;93(16). pii: e00211-19. doi: 10.1128/JVI.00211-19. Print 2019 Aug 15.

PMID:
31142663
3.

Extracellular Vesicles Released by Allogeneic Human Cardiac Stem/Progenitor Cells as Part of Their Therapeutic Benefit.

Hocine HR, Brunel S, Chen Q, Giustiniani J, San Roman MJ, Ferrat YJ, Palacios I, de la Rosa O, Lombardo E, Bensussan A, Charron D, Jabrane-Ferrat N, Al-Daccak R.

Stem Cells Transl Med. 2019 Sep;8(9):911-924. doi: 10.1002/sctm.18-0256. Epub 2019 Mar 28.

4.

Peripheral Plasma and Semen Cytokine Response to Zika Virus in Humans.

Mansuy JM, El Costa H, Gouilly J, Mengelle C, Pasquier C, Martin-Blondel G, Izopet J, Jabrane-Ferrat N.

Emerg Infect Dis. 2019 Apr;25(4):823-825. doi: 10.3201/eid2504.171886.

5.

Genotype specific pathogenicity of hepatitis E virus at the human maternal-fetal interface.

Gouilly J, Chen Q, Siewiera J, Cartron G, Levy C, Dubois M, Al-Daccak R, Izopet J, Jabrane-Ferrat N, El Costa H.

Nat Commun. 2018 Nov 12;9(1):4748. doi: 10.1038/s41467-018-07200-2.

6.

Human Cardiac-Derived Stem/Progenitor Cells Fine-Tune Monocyte-Derived Descendants Activities toward Cardiac Repair.

Dam N, Hocine HR, Palacios I, DelaRosa O, Menta R, Charron D, Bensussan A, El Costa H, Jabrane-Ferrat N, Dalemans W, Lombardo E, Al-Daccak R.

Front Immunol. 2017 Oct 26;8:1413. doi: 10.3389/fimmu.2017.01413. eCollection 2017.

7.

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.

Sci Rep. 2017 Oct 20;7:46888. doi: 10.1038/srep46888.

8.

Corrigendum: Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.

Sci Rep. 2017 Mar 16;7:44720. doi: 10.1038/srep44720. No abstract available.

9.

Minimizing the risk of allo-sensitization to optimize the benefit of allogeneic cardiac-derived stem/progenitor cells.

Hocine HR, Costa HE, Dam N, Giustiniani J, Palacios I, Loiseau P, Bensussan A, Borlado LR, Charron D, Suberbielle C, Jabrane-Ferrat N, Al-Daccak R.

Sci Rep. 2017 Jan 24;7:41125. doi: 10.1038/srep41125. Erratum in: Sci Rep. 2017 Mar 16;7:44720. Sci Rep. 2017 Oct 20;7:46888.

10.

ZIKA virus reveals broad tissue and cell tropism during the first trimester of pregnancy.

El Costa H, Gouilly J, Mansuy JM, Chen Q, Levy C, Cartron G, Veas F, Al-Daccak R, Izopet J, Jabrane-Ferrat N.

Sci Rep. 2016 Oct 19;6:35296. doi: 10.1038/srep35296.

11.

Natural cytotoxicity receptor splice variants orchestrate the distinct functions of human natural killer cell subtypes.

Siewiera J, Gouilly J, Hocine HR, Cartron G, Levy C, Al-Daccak R, Jabrane-Ferrat N.

Nat Commun. 2015 Dec 15;6:10183. doi: 10.1038/ncomms10183.

12.

Natural killer cell crosstalk with allogeneic human cardiac-derived stem/progenitor cells controls persistence.

Boukouaci W, Lauden L, Siewiera J, Dam N, Hocine HR, Khaznadar Z, Tamouza R, Borlado LR, Charron D, Jabrane-Ferrat N, Al-Daccak R.

Cardiovasc Res. 2014 Nov 1;104(2):290-302. doi: 10.1093/cvr/cvu208. Epub 2014 Sep 11.

PMID:
25213554
13.

TGF-β-induced (TGFBI) protein in melanoma: a signature of high metastatic potential.

Lauden L, Siewiera J, Boukouaci W, Ramgolam K, Mourah S, Lebbe C, Charron D, Aoudjit F, Jabrane-Ferrat N, Al-Daccak R.

J Invest Dermatol. 2014 Jun;134(6):1675-1685. doi: 10.1038/jid.2014.20. Epub 2014 Jan 17.

14.

The up side of decidual natural killer cells: new developments in immunology of pregnancy.

Jabrane-Ferrat N, Siewiera J.

Immunology. 2014 Apr;141(4):490-7. doi: 10.1111/imm.12218. Review.

15.

Human cytomegalovirus infection elicits new decidual natural killer cell effector functions.

Siewiera J, El Costa H, Tabiasco J, Berrebi A, Cartron G, Le Bouteiller P, Jabrane-Ferrat N.

PLoS Pathog. 2013;9(4):e1003257. doi: 10.1371/journal.ppat.1003257. Epub 2013 Apr 4. Erratum in: PLoS Pathog. 2013 May;9(5). doi:10.1371/annotation/94476def-de2e-4a6e-b0c2-2f2d2ccae784. Bouteiller, Philippe [corrected to Le Bouteiller, Philippe].

16.

A novel antiangiogenic and vascular normalization therapy targeted against human CD160 receptor.

Chabot S, Jabrane-Ferrat N, Bigot K, Tabiasco J, Provost A, Golzio M, Noman MZ, Giustiniani J, Bellard E, Brayer S, Aguerre-Girr M, Meggetto F, Giuriato S, Malecaze F, Galiacy S, Jaïs JP, Chose O, Kadouche J, Chouaib S, Teissié J, Abitbol M, Bensussan A, Le Bouteiller P.

J Exp Med. 2011 May 9;208(5):973-86. doi: 10.1084/jem.20100810. Epub 2011 Apr 11.

17.

CD160: a unique activating NK cell receptor.

Le Bouteiller P, Tabiasco J, Polgar B, Kozma N, Giustiniani J, Siewiera J, Berrebi A, Aguerre-Girr M, Bensussan A, Jabrane-Ferrat N.

Immunol Lett. 2011 Aug 30;138(2):93-6. doi: 10.1016/j.imlet.2011.02.003. Epub 2011 Feb 13. Review.

PMID:
21324341
18.

The human decidual NK-cell response to virus infection: what can we learn from circulating NK lymphocytes?

Le Bouteiller P, Siewiera J, Casart Y, Aguerre-Girr M, El Costa H, Berrebi A, Tabiasco J, Jabrane-Ferrat N.

J Reprod Immunol. 2011 Mar;88(2):170-5. doi: 10.1016/j.jri.2010.12.005. Epub 2011 Jan 28. Review.

PMID:
21277025
19.

Critical and differential roles of NKp46- and NKp30-activating receptors expressed by uterine NK cells in early pregnancy.

El Costa H, Casemayou A, Aguerre-Girr M, Rabot M, Berrebi A, Parant O, Clouet-Delannoy M, Lombardelli L, Jabrane-Ferrat N, Rukavina D, Bensussan A, Piccinni MP, Le Bouteiller P, Tabiasco J.

J Immunol. 2008 Sep 1;181(5):3009-17.

20.

Inhibition of proteasome activity impairs centrosome-dependent microtubule nucleation and organization.

Didier C, Merdes A, Gairin JE, Jabrane-Ferrat N.

Mol Biol Cell. 2008 Mar;19(3):1220-9. Epub 2007 Dec 19.

21.

Challenge with mammary tumor cells expressing MHC class II and CD80 prevents the development of spontaneously arising tumors in MMTV-neu transgenic mice.

Jabrane-Ferrat N, Campbell MJ, Esserman LJ, Peterlin BM.

Cancer Gene Ther. 2006 Nov;13(11):1002-10. Epub 2006 Jul 7.

PMID:
16841083
22.

Expression of MHC II genes.

Drozina G, Kohoutek J, Jabrane-Ferrat N, Peterlin BM.

Curr Top Microbiol Immunol. 2005;290:147-70. Review.

PMID:
16480042
23.

MHC class II enhanceosome: how is the class II transactivator recruited to DNA-bound activators?

Jabrane-Ferrat N, Nekrep N, Tosi G, Esserman L, Peterlin BM.

Int Immunol. 2003 Apr;15(4):467-75.

PMID:
12663676
24.
25.

Mutation in a winged-helix DNA-binding motif causes atypical bare lymphocyte syndrome.

Nekrep N, Jabrane-Ferrat N, Wolf HM, Eibl MM, Geyer M, Peterlin BM.

Nat Immunol. 2002 Nov;3(11):1075-81. Epub 2002 Sep 30.

PMID:
12368908
26.
27.

NF-kappaB binds P-TEFb to stimulate transcriptional elongation by RNA polymerase II.

Barboric M, Nissen RM, Kanazawa S, Jabrane-Ferrat N, Peterlin BM.

Mol Cell. 2001 Aug;8(2):327-37.

28.

Analysis of ankyrin repeats reveals how a single point mutation in RFXANK results in bare lymphocyte syndrome.

Nekrep N, Geyer M, Jabrane-Ferrat N, Peterlin BM.

Mol Cell Biol. 2001 Aug;21(16):5566-76.

29.
30.
31.

Prostaglandin E2 enhancement of interferon-gamma production by antigen-stimulated type 1 helper T cells.

Bloom D, Jabrane-Ferrat N, Zeng L, Wu A, Li L, Lo D, Turck CW, An S, Goetzl EJ.

Cell Immunol. 1999 May 25;194(1):21-7.

PMID:
10357877
32.

Enhancement by vasoactive intestinal peptide of gamma-interferon production by antigen-stimulated type 1 helper T cells.

Jabrane-Ferrat N, Bloom D, Wu A, Li L, Lo D, Sreedharan SP, Turck CW, Goetzl AE.

FASEB J. 1999 Feb;13(2):347-53.

PMID:
9973323
33.

Vasoactive intestinal peptide enhancement of antigen-induced differentiation of a cultured line of mouse thymocytes.

Pankhaniya R, Jabrane-Ferrat N, Gaufo GO, Sreedharan SP, Dazin P, Kaye J, Goetzl EJ.

FASEB J. 1998 Jan;12(1):119-27.

PMID:
9438417
34.

Assembly of functional regulatory complexes on MHC class II promoters in vivo.

Fontes JD, Jabrane-Ferrat N, Peterlin BM.

J Mol Biol. 1997 Jul 18;270(3):336-45.

PMID:
9237901
35.

Sequence-independent inhibition of RNA transcription by DNA dumbbells and other decoys.

Lim CS, Jabrane-Ferrat N, Fontes JD, Okamoto H, Garovoy MR, Peterlin BM, Hunt CA.

Nucleic Acids Res. 1997 Feb 1;25(3):575-81.

36.
37.

Binding and cooperative interactions between two B cell-specific transcriptional coactivators.

Fontes JD, Jabrane-Ferrat N, Toth CR, Peterlin BM.

J Exp Med. 1996 Jun 1;183(6):2517-21.

38.

The function of the octamer-binding site in the DRA promoter.

Voliva CF, Jabrane-Ferrat N, Peterlin BM.

Immunogenetics. 1996;43(1-2):20-6.

PMID:
8537118
39.

Ets-1 activates the DRA promoter in B cells.

Jabrane-Ferrat N, Peterlin BM.

Mol Cell Biol. 1994 Nov;14(11):7314-21.

40.

The major histocompatibility complex class II promoter-binding protein RFX (NF-X) is a methylated DNA-binding protein.

Zhang XY, Jabrane-Ferrat N, Asiedu CK, Samac S, Peterlin BM, Ehrlich M.

Mol Cell Biol. 1993 Nov;13(11):6810-8.

41.

Effect of gamma interferon on HLA class-I and -II transcription and protein expression in human breast adenocarcinoma cell lines.

Jabrane-Ferrat N, Faille A, Loiseau P, Poirier O, Charron D, Calvo F.

Int J Cancer. 1990 Jun 15;45(6):1169-76.

PMID:
2112515
42.

Recombinant gamma interferon provokes resistance of human breast cancer cells to spontaneous and IL-2 activated non-MHC restricted cytotoxicity.

Jabrane-Ferrat N, Calvo F, Faille A, Lagabrielle JF, Boisson N, Quillet A, Fradelizi D.

Br J Cancer. 1990 Apr;61(4):558-62.

Supplemental Content

Loading ...
Support Center